Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 12.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12
We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 851 | 109 | -28 | 71 | N/A |
| 9/30/2023 | 1,023 | 191 | -107 | -29 | N/A |
| 6/30/2023 | 1,283 | 242 | -85 | -3 | N/A |
| 3/31/2023 | 1,080 | 142 | -72 | 22 | N/A |
| 12/31/2022 | 1,031 | 138 | 78 | 165 | N/A |
| 9/30/2022 | 1,158 | 132 | 185 | 318 | N/A |
| 6/30/2022 | 1,013 | 112 | 142 | 272 | N/A |
| 3/31/2022 | 1,155 | 213 | 128 | 276 | N/A |
| 12/31/2021 | 1,140 | 213 | 149 | 269 | N/A |
| 9/30/2021 | 1,036 | 198 | 139 | 241 | N/A |
| 6/30/2021 | 997 | 201 | 28 | 108 | N/A |
| 3/31/2021 | 925 | 188 | 11 | 66 | N/A |
| 12/31/2020 | 834 | 165 | 71 | 113 | N/A |
| 9/30/2020 | 901 | 191 | 120 | 151 | N/A |
| 6/30/2020 | 874 | 165 | 197 | 229 | N/A |
| 3/31/2020 | 980 | 204 | N/A | N/A | N/A |
| 12/31/2019 | 1,029 | 227 | 229 | 269 | N/A |
| 9/30/2019 | 848 | 151 | 174 | 217 | N/A |
| 6/30/2019 | 837 | 151 | 220 | 261 | N/A |
| 3/31/2019 | 678 | 91 | N/A | N/A | N/A |
| 12/31/2018 | 742 | 112 | 141 | 180 | N/A |
| 9/30/2018 | 632 | 95 | 69 | 110 | N/A |
| 6/30/2018 | 521 | 78 | -3 | 41 | N/A |
| 3/31/2018 | 510 | 77 | -11 | 42 | N/A |
| 12/31/2017 | 498 | 75 | -18 | 43 | N/A |
| 9/30/2017 | 575 | 109 | N/A | 80 | N/A |
| 6/30/2017 | 652 | 142 | N/A | 117 | N/A |
| 3/31/2017 | 637 | 141 | N/A | 129 | N/A |
| 12/31/2016 | 622 | 139 | N/A | 141 | N/A |
| 9/30/2016 | 615 | 136 | N/A | 131 | N/A |
| 6/30/2016 | 607 | 134 | N/A | 121 | N/A |
| 3/31/2016 | 593 | 131 | N/A | 109 | N/A |
| 12/31/2015 | 579 | 128 | N/A | 96 | N/A |
| 9/30/2015 | 556 | 125 | N/A | 102 | N/A |
| 6/30/2015 | 532 | 122 | N/A | 107 | N/A |
| 3/31/2015 | 501 | 120 | N/A | 98 | N/A |
| 12/31/2014 | 471 | 118 | N/A | 88 | N/A |
| 9/30/2014 | 464 | 111 | N/A | N/A | N/A |
| 6/30/2014 | 412 | 96 | N/A | 105 | N/A |
| 3/31/2014 | 446 | 98 | N/A | N/A | N/A |
| 12/31/2013 | 416 | 87 | N/A | 89 | N/A |
| 9/30/2013 | 367 | 76 | N/A | N/A | N/A |
| 6/30/2013 | 307 | 65 | N/A | 71 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1349's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if 1349's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1349's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1349's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 1349's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1349's Return on Equity is forecast to be high in 3 years time